|
1
|
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.
|
Neuro Oncol
|
2010
|
3.67
|
|
2
|
Effect of bevacizumab on radiation necrosis of the brain.
|
Int J Radiat Oncol Biol Phys
|
2007
|
2.10
|
|
3
|
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway.
|
J Natl Cancer Inst
|
2003
|
1.86
|
|
4
|
VEGF Trap induces antiglioma effect at different stages of disease.
|
Neuro Oncol
|
2008
|
1.77
|
|
5
|
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
|
Mol Cancer Ther
|
2005
|
1.66
|
|
6
|
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.
|
Cancer
|
2011
|
1.50
|
|
7
|
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.
|
Neuro Oncol
|
2008
|
1.23
|
|
8
|
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.
|
J Neurooncol
|
2014
|
1.17
|
|
9
|
Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis.
|
Ann Neurol
|
2003
|
1.12
|
|
10
|
Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells.
|
J Proteome Res
|
2010
|
1.09
|
|
11
|
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.
|
J Neurooncol
|
2009
|
1.07
|
|
12
|
Method for lipidomic analysis: p53 expression modulation of sulfatide, ganglioside, and phospholipid composition of U87 MG glioblastoma cells.
|
Anal Chem
|
2007
|
1.02
|
|
13
|
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
|
J Neurooncol
|
2006
|
1.02
|
|
14
|
Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.
|
Neuro Oncol
|
2002
|
0.99
|
|
15
|
Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.
|
Oncotarget
|
2014
|
0.98
|
|
16
|
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.
|
J Clin Oncol
|
2004
|
0.98
|
|
17
|
A novel E1A-E1B mutant adenovirus induces glioma regression in vivo.
|
Oncogene
|
2004
|
0.97
|
|
18
|
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
|
J Neurooncol
|
2006
|
0.95
|
|
19
|
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.
|
Neuro Oncol
|
2008
|
0.93
|
|
20
|
Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation.
|
J Proteome Res
|
2010
|
0.90
|
|
21
|
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
|
Cancer Chemother Pharmacol
|
2012
|
0.89
|
|
22
|
Mechanisms of action of rapamycin in gliomas.
|
Neuro Oncol
|
2005
|
0.87
|
|
23
|
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
|
J Neurooncol
|
2010
|
0.87
|
|
24
|
Integrated chromosome 19 transcriptomic and proteomic data sets derived from glioma cancer stem-cell lines.
|
J Proteome Res
|
2013
|
0.86
|
|
25
|
Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression.
|
J Proteome Res
|
2007
|
0.85
|
|
26
|
Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.
|
Int J Oncol
|
2004
|
0.84
|
|
27
|
Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, irinotecan.
|
Glycoconj J
|
2009
|
0.82
|
|
28
|
Chromosome 19 annotations with disease speciation: a first report from the Global Research Consortium.
|
J Proteome Res
|
2012
|
0.82
|
|
29
|
Determining and interpreting correlations in lipidomic networks found in glioblastoma cells.
|
BMC Syst Biol
|
2010
|
0.81
|
|
30
|
Integrative biological analysis for neuropsychopharmacology.
|
Neuropsychopharmacology
|
2013
|
0.79
|
|
31
|
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.
|
Cancer
|
2011
|
0.78
|